STAT5B and prolymphocytic leukemia: These findings align with our hypothesis that constitutive JAK/STAT activation is independent of specific JAK/STAT mutations, making STAT3/STAT5 inhibition a promising target for T-PLL cases, irrespective of their JAK/STAT molecular profile.